%PDF-1.3
%
4 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
13 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
9 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
14 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
22 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
15 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
17 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
16 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
12 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
20 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
3 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
6 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
7 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
8 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
19 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
21 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
1 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
10 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
11 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
18 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
24 0 obj
<>stream
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
Arbortext Advanced Print Publisher 9.0.114/W
2017-04-11T03:58:57-07:00
2015-10-13T06:09:04+05:30
application/pdf
ARS-2014-6077-ver9-Abdel-Fatah_4P 2262..2268
uuid:a5cc856a-21da-44d2-89cc-42c038b6d16b
uuid:02058d70-a726-4d36-bfd6-ff610b9cbeb5
endstream
endobj
25 0 obj
<>stream
x+ |
endstream
endobj
26 0 obj
<>stream
xS**T0T0 BiUD* :
endstream
endobj
27 0 obj
<>stream
x+ |
endstream
endobj
28 0 obj
<>stream
xS**T0T0 BiU !D. _e1
endstream
endobj
29 0 obj
<>stream
x+ |
endstream
endobj
30 0 obj
<>stream
xS**T0T0 Bih] D. pa
endstream
endobj
31 0 obj
<>stream
x+ |
endstream
endobj
32 0 obj
<>stream
xS**T0T0 Bih]9D. qaj
endstream
endobj
33 0 obj
<>stream
x+ |
endstream
endobj
34 0 obj
<>stream
xS**T0T0 Bih]D. r^j
endstream
endobj
35 0 obj
<>stream
x+ |
endstream
endobj
36 0 obj
<>stream
xS**T0T0 BiUD* 8
endstream
endobj
37 0 obj
<>stream
x+ |
endstream
endobj
38 0 obj
<>stream
xS**T0T0 BiU)D* 9V
endstream
endobj
40 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.843 0 0 9.843 59.7543 522.992 Tm
0 0 0 rg
0 Tc
0 Tw
[(wh)14.2(ic)19.6(h)-196.9(i)0(s)-192.2(a)-198.1(st)20.9(ro)15.1(ng)-186.5(st)20.9(im)19.5(ul)20.7(us)-192.1(fo)20.9(r)-202.7(a)0(c)18.5(t)0(i)20.6(v)0(a)19.7(t)0(i)20.6(o)0(n)-192.3(o)0(f)-186.5(D)0(N)19.1(A)-203.6(ba)19.7(se)-193.2(ex)19.7(ci)19.6(si)20.9(on)]TJ
0 -1.1116 TD
[(re)14(pa)19.7(ir)-250(\(B)19.8(ER)18.6(\),)-252.2(a)-261.4(c)0(o)19.7(m)0(p)19.6(l)0(e)13.8(x)-260.3(pa)19.7(th)20.7(wa)18.8(y)-260.3(t)0(h)15(a)0(t)-251.2(i)0(n)20.7(c)0(l)19.5(u)0(d)20.8(e)0(s)-256.6(k)0(e)19.7(y)-260.3(enz)11.7(yme)17.3(s,)]TJ
T*
[(inc)12.7(lud)13.9(ing)-400.8(AP)-406.1(end)12.8(onu)14(cle)11.5(as)14.1(e)-411.2(1)-410(\(AP)13.3(E1\))12.8(,)-412.4(DNA)-403.3(po)15.1(lym)12.6(era)11.7(se)]TJ
/F5 1 Tf
23.7415 0 TD
(b)Tj
/F4 1 Tf
-23.7415 -1.1174 TD
[(\(po)14(l)]TJ
/F5 1 Tf
2.1426 0 TD
(b)Tj
/F4 1 Tf
.5472 0 TD
[(\),)-540.1(ap)-534.2(end)12.8(onu)14(cle)11.5(ase)-535.3(1)-542.5(\(FE)13(N1\))13.1(,)-539.1(pol)13.8(y)-542.5(\(AD)12.3(P-r)14.2(ibo)13.8(se\))]TJ
-2.6898 -1.1116 TD
[(pol)13.8(yme)11.6(ras)13(e)-290.2(1)-289.1(\(PA)13.3(RP1)13.1(\),)-281(X-r)13.2(ay)-285.6(cro)12.8(ss-)14.4(com)11.6(ple)12.7(me)12.7(nta)12.7(tio)13.7(n)-289.1(gro)14(up)]TJ
T*
[(1)-427.3(pro)19.8(tei)12.6(n)-421.6(\(XR)12.1(CC1)11.9(\),)-419.2(and)-413.4(DNA)-414.9(lig)13.7(ase)11.9(s)-421.4(\(4\))14(.)-423.9(I)0(f)-416.8(BER)-415.5(is)-416.8(sub)14.2(-)]TJ
T*
[(opt)13.8(ima)11.5(l,)-286.9(DNA)-282.4(rep)12.8(air)-286.8(int)13.7(erm)17.4(edi)12.7(ate)11.5(s)-294.6(m)0(a)12.7(y)-294.8(be)-285.6(con)12.8(ver)12.8(ted)-286.8(to)-284.5(sin)14(-)]TJ
0 -1.1174 TD
[(gle)12.7(-st)14.1(ran)12.8(d)-479.1(bre)12.9(aks)-470.8(\(SS)14.3(B\))-469.7(and)-471(the)12.7(n)-479.2(t)0(o)-474.6(dou)14(ble)18.4(-st)14.1(ran)12.9(d)-479.2(bre)12.9(aks)]TJ
0 -1.1116 TD
.0196 Tc
[(\(DSB)-5.6(s\))-304(during)-304(r)1.3(eplic)-5.7(ation.)-300.6(D)-5.4(S)1.4(Bs)-303.8(activa)-5.7(t)1.1(e)-299.4(k)-4.5(ey)-298.3(D)-5.4(N).4(A)-299.1(d)-4.5(am-)]TJ
T*
.0189 Tc
[(a)-6.4(g).5(e)-369.3(s)-5(ens)-5(i).4(n)-5.2(g)-368.1(ata)-6.4(x).5(ia)-375(tel)-5.4(a)-.6(ng)-5.2(iec)-6.4(t).4(as)-5(ia)-369.3(m)-6.5(u).5(ta)-6.4(ted)-373.9(\().6(ATM)-6.1(\)).6(,)-370.4(D)-.3(N)-6.1(A)-.3(-)]TJ
0 -1.1174 TD
0 Tc
[(dependent)-243.9(protein)-239.5(kinase)-245(catalytic)-245.5(subunit)-238.2(\(DNA-PKcs\),)-243.3(and)]TJ
0 -1.1116 TD
[(ataxia)-200.4(telangiectasia)-201.4(mutated)-195.8(and)-194.5(Rad3)-190.9(related)-201.5(\(ATR\))-192.9(protein)]TJ
T*
[(kinases.)-410.6(Activated)-412.1(ATR)-409.6(and)-407.6(ATM)-403.7(phosphorylate)-408.3(Chk1)-408.6(or)]TJ
0 -1.1174 TD
[(Chk2,)-187.4(respectively;)-186.3(these,)-184(in)-180.9(turn,)-180.7(modulate)-185.4(a)-180.8(number)-187.5(of)-180.7(other)]TJ
0 -1.1116 TD
[(proteins)-292.2(involved)-292.5(in)-290.3(DNA)-293.9(repair,)-294.7(cell)-295(cycle)-291.3(control,)-294.8(and)-286.7(ap-)]TJ
T*
[(optosis)-347.4(\(7\).)-340.7(Our)-344(hypothesis)-346.1(is)-342(that)-345.6(sub-optimal)-343(DNA)-345.7(repair)]TJ
0 -1.1174 TD
[(ma)18.4(y)-317.9(a)0(c)18.5(c)0(e)12.8(l)0(e)19.6(r)0(a)19.7(t)0(e)-308.8(R)0(O)18.9(S)0(-)21(i)0(n)20.7(d)0(u)20.8(c)0(e)12.8(d)-317.9(mu)19.6(ta)19.6(ge)19.7(ne)19.7(si)20.9(s)-317.7(a)0(n)19.7(d)-323.6(le)19.6(ad)-308.6(to)-307.6(a)-319(m)0(u)19.6(-)]TJ
0 -1.1116 TD
[(ta)19.6(to)15(r)-375.4(p)0(h)15.1(e)0(n)19.7(o)0(t)20.7(y)0(p)20.8(e)-382.4(ch)19.7(ar)19.7(ac)18.5(te)19.6(ri)20.7(ze)18.5(d)-381.2(b)0(y)-370.8(a)0(g)19.7(g)0(r)20.9(e)0(s)14.1(s)0(i)20.9(v)0(e)-372(b)0(e)19.7(h)0(a)19.7(v)0(i)20.7(o)0(r)-370.8(i)0(n)-370.9(e)0(s)19.9(-)]TJ
T*
[(tr)15(og)20.8(en)19.7(/E)19.5(R-)19.8(dr)20.9(iv)20.7(en)-383.5(br)20.9(ea)18.5(st)-382.3(ca)18.5(nc)19.7(er)19.7(.)-389.3(W)0(e)-385.8(i)0(n)20.7(v)0(e)19.7(s)0(t)20.9(i)0(g)20.7(a)0(t)19.5(e)0(d)-383.5(1)0(4)20.8(0)0(6)-382.3(E)0(R)]TJ
/F7 1 Tf
7.3823 0 0 6.5614 294.5763 330.1227 Tm
(+)Tj
/F4 1 Tf
9.843 0 0 9.843 59.7543 314.8157 Tm
[(ea)18.5(rl)15(y-)20.9(st)20.9(ag)19.7(e)-399.7(b)0(r)20.9(e)0(a)18.5(s)0(t)-388(c)0(a)18.5(n)0(c)19.7(e)0(r)19.7(s)-398.3(wi)19.8(th)-388.2(20)-382.3(ye)13.9(ar)19.7(s)-387.9(lo)20.7(ng)20.8(-t)20.7(er)19.7(m)-399.7(c)0(l)19.6(i)0(n)20.7(i)0(c)19.6(a)0(l)]TJ
0 -1.1174 TD
[(fo)15.1(ll)20.6(ow)20(-u)20.9(p)-237.2(d)0(a)19.7(t)0(a)-233.9(f)0(o)20.9(r)-237.2(po)20.8(l)]TJ
/F5 1 Tf
8.8815 0 TD
(b)Tj
/F4 1 Tf
.5414 0 TD
[(,)-239.6(F)0(E)19.8(N)0(1)20(,)-239.6(AP)20.1(E1)19.6(,)-239.6(X)0(R)18.9(C)0(C)18.8(1)0(,)-229.2(s)0(i)20.9(n)0(g)20.8(l)0(e)19.6(-)0(s)15.3(t)0(r)20.7(a)0(n)19.7(d)]TJ
-9.4229 -1.1116 TD
-.023 Tc
[(mo)4.7(nof)4.7(uncti)4.6(onal)-312.2(u)-1.1(r)4.7(a)-2.2(cil)-312.2(g)-1.1(l)4.6(y)-1.1(cosy)4.7(las)4.9(e)-2.2(-)4.7(1)-312.1(\(SMUG1\),)-308.7(PARP1)4.7(,)-314.4(ATR,)]TJ
T*
-.0221 Tc
[(ATM,)-181(DNA-)5.6(PKcs,)-181(C)4.6(hk1)5.6(,)-181(C)-1.2(h)5.6(k2,)-175.3(p53)5.6(,)-181(b)-.2(reas)5.8(t)-184.6(c)4.4(an)5.6(cer)-178.7(su)5.6(scept)5.5(i)-.3(bi)5.5(li)5.5(ty)]TJ
0 -1.1174 TD
-.0227 Tc
[(gen)5(e)-278.4(1)-283(\()5(BRCA1\),)-273.8(a)-1.9(nd)-277.2(t)4.9(opo)5(iso)5(m)-2(erase)-278.4(2)-283(\()5(T)-1.9(OPO2)5(\))-277.2(e)-1.9(xp)5(ressi)4.9(on.)]TJ
/F10 1 Tf
8.9663 0 0 8.9663 59.7543 249.0519 Tm
0 Tc
[(Deregulated)-339.9(BER)-333.7(is)-331.6(independently)-334(associated)]TJ
0 -1.2266 TD
[(with)-336.5(poor)-331.5(survival)-338.6(in)-330.2(ER)]TJ
/F7 1 Tf
6.7246 0 0 5.9768 156.1322 242.0787 Tm
(+)Tj
/F10 1 Tf
8.9663 0 0 8.9663 163.9559 238.0535 Tm
[(breast)-334.6(cancers)]TJ
/F4 1 Tf
9.843 0 0 9.843 69.7323 221.6125 Tm
[(The)-541.3(initial)-539.4(multivariate)-536.9(model)-537.9(included)-541.3(Pol)]TJ
/F5 1 Tf
19.3065 0 TD
(b)Tj
/F4 1 Tf
.5529 0 TD
[(,)-533.3(FEN1,)]TJ
-20.8732 -1.1116 TD
[(APE1,)-626(XRCC1,)-629.2(SMUG1,)-627.7(PARP1,)-626.8(ATR,)-626.1(ATM,)-626(CHK1,)]TJ
T*
[(CHK2,)-298.6(p53,)-294.7(BRCA1,)-295.1(DNA-PKcs,)-304.5(TOPO2,)-294(lymph)-294.9(node)-293.6(sta-)]TJ
25.5097 53.381 TD
[(tus,)-208.3(and)-206.1(histological)-211.8(grade.)-212.8(Nonsignicant)-213.4(markers)-212.6(were)-209.2(then)]TJ
0 -1.1174 TD
[(removed)-305(using)-304.9(a)-301.8(backward)-306.9(stepwise)-311.4(exclusion)-306(method)-302.9(until)]TJ
0 -1.1116 TD
[(only)-229.2(signicant)-238(markers)-235.6(remained.)-230.2(As)-233.3(shown)-236.6(in)-227(Table)-233.8(1,)-234.9(low)]TJ
T*
[(XRCC1)-648.8(\()]TJ
/F6 1 Tf
4.3659 0 TD
(p)Tj
/F7 1 Tf
.6624 0 TD
(<)Tj
/F4 1 Tf
.72 0 TD
[(0.01\),)-644.8(low)-649.4(APE1)-645.6(\()]TJ
/F6 1 Tf
8.6568 0 TD
(p)Tj
/F7 1 Tf
.6681 0 TD
(<)Tj
/F4 1 Tf
.7142 0 TD
[(0.01\),)-650.6(low)-643.6(SMUG1)]TJ
-15.7874 -1.1116 TD
(\()Tj
/F6 1 Tf
.5011 0 TD
(p)Tj
/F7 1 Tf
.6624 0 TD
(<)Tj
/F4 1 Tf
.72 0 TD
[(0.01\),)-333.8(and)-338.5(high)-332.8(FEN1)-340.4(\()]TJ
/F6 1 Tf
9.7857 0 TD
(p)Tj
/F7 1 Tf
.6681 0 TD
(<)Tj
/F4 1 Tf
.72 0 TD
[(0.01\))-336.1(remain)-338.6(independently)]TJ
-13.0572 -1.1174 TD
[(associated)-263.2(with)-259(poor)-257.8(breast)-262.3(cancer-specic)-265.2(survival)-263.4(\(BCSS\).)]TJ
0 -1.1116 TD
[(Lymph)-589.7(node)-593.1(stage)-595.3(\()]TJ
/F6 1 Tf
9.181 0 TD
(p)Tj
/F7 1 Tf
.6681 0 TD
(<)Tj
/F4 1 Tf
.7142 0 TD
[(0.00001\))-592.8(and)-597.7(histological)-592(grade)]TJ
-10.5633 -1.1116 TD
(\()Tj
/F6 1 Tf
.5011 0 TD
(p)Tj
/F7 1 Tf
.6624 0 TD
(<)Tj
/F4 1 Tf
.72 0 TD
[(0.00001\))-564(also)-569.9(remain)-563.2(independently)-571.1(associated)-568.5(with)]TJ
-1.8834 -1.1174 TD
[(poor)-280.8(BCSS.)]TJ
/F10 1 Tf
8.9663 0 0 8.9663 310.8472 615.5715 Tm
[(BER)-333.7(prognostic)-333.6(index)-332.2(straties)-336(patients)-337.4(into)-331.8(distinct)]TJ
0 -1.2266 TD
[(prognostic)-333.6(groups)-335.4(in)-330.2(ER)]TJ
/F7 1 Tf
6.7246 0 0 5.9768 408.6991 608.5983 Tm
(+)Tj
/F10 1 Tf
8.9663 0 0 8.9663 416.5227 604.5731 Tm
[(breast)-334.6(cancers)]TJ
/F4 1 Tf
9.843 0 0 9.843 320.8251 588.1321 Tm
[(A)-313(BER)-317.6(prognostic)-317.5(index)-312.1(score)-318.6(\(see)-317.5(Notes)-318.5(section\))-316.4(incor-)]TJ
-1.0137 -1.1116 TD
[(porating)-246.3(XRCC1,)-243.3(APE1,)-245.9(SMUG1,)-247.6(and)-246.4(FEN1)-242.5(was)-247(developed)]TJ
T*
[(and)-280.9(can)-282.1(be)-279.8(described)-284(by)-278.7(the)-281.1(following)-287.6(formula:)]TJ
1.0137 -1.1116 TD
-.0208 Tc
[(B)-5.6(E)-20.8(R)-180.7(p)-20.8(ro)-20.8(gn)-20.8(os)-20.8(ti)-20.8(c)-179.8(i)-20.8(nd)-20.8(ex)-194.7(s)-20.8(c)-.9(or)-20.8(e)]TJ
/F7 1 Tf
10.9722 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.7084 0 TD
[(XR)18.9(CC)24.5(1)-173.9(\()0(h)20.9(i)0(g)26.5(h)0(:)]TJ
/F7 1 Tf
6.0247 0 TD
(-)Tj
/F4 1 Tf
.7027 0 TD
[(0.)18.5(20)20.8(,)-170.5(l)16.1(ow)20(:)-174(1)16.2(\))]TJ
/F7 1 Tf
-19.3584 -1.1174 TD
(+)Tj
/F4 1 Tf
.7084 0 TD
[(FE)19.8(N1)-285.3(\(h)20.9(i)16.1(g)0(h)20.8(:)-295(0.)18.5(20)20.8(,)-291.4(l)0(o)20.7(w)0(:)-285.4(1)0(\))]TJ
/F7 1 Tf
10.5575 0 TD
(+)Tj
/F4 1 Tf
.7084 0 TD
[(SM)25.9(UG)19.1(1)-294.8(\()0(h)20.9(i)0(g)20.7(h)0(:)]TJ
/F7 1 Tf
6.4278 0 TD
(-)Tj
/F4 1 Tf
.7084 0 TD
[(0.)24.3(21)20.8(,)-297.2(l)0(o)26.5(w)0(:)-291.2(1)16.2(\))]TJ
/F7 1 Tf
-19.1107 -1.1116 TD
(+)Tj
/F4 1 Tf
.7084 0 TD
[(AP)20.1(E1)-256.8(\(h)20.9(ig)20.7(h:)]TJ
/F7 1 Tf
5.3968 0 TD
(-)Tj
/F4 1 Tf
.7084 0 TD
[(0.)24.3(25)20.8(,)-268.4(l)0(o)20.7(w)0(:)-256.6(1)0(\))]TJ
-5.8634 -1.1116 TD
[(Sub-group)-309.2(1)-312.1(was)-310.4(dened)-314(as)-314.2(tumors)-307.2(with)-316.6(BER)-311.8(prognostic)]TJ
-1.0137 -1.1174 TD
[(index)-404.2(score)-410.8(ranging)-406.4(from)]TJ
/F7 1 Tf
10.7361 0 TD
(-)Tj
/F4 1 Tf
.72 0 TD
[(0.46)-409.9(to)-405.5(0.34.)-401.8(Sub-group)-407.1(2)-410(was)]TJ
-11.4561 -1.1116 TD
[(dened)-296.8(as)-296.9(tumors)-295.7(with)-299.3(BER)-294.6(prognostic)-300.2(index)-294.8(score)-295.6(ranging)]TJ
T*
[(from)-316.6(0.74)-323.5(to)-319.1(1.59.)-321.2(Sub-group)-320.7(3)-317.9(was)-321.9(dened)-319.8(as)-325.7(tumors)-318.8(with)]TJ
0 -1.1174 TD
[(BER)-260(prognostic)-265.6(index)-260.2(score)-261(ranging)-262.4(from)-264.7(1.95)-260.2(to)-255.8(2.80.)-263.6(Sub-)]TJ
0 -1.1116 TD
[(group)-270.4(4)-271.8(was)-270.1(dened)-273.7(as)-273.9(tumors)-272.7(with)-270.5(a)-273(BER)-271.5(prognostic)-271.4(index)]TJ
T*
[(score)-284.1(of)-278.6(more)-283.2(than)-282.2(3.2.)]TJ
1.0137 -1.1116 TD
[(Survival)-395.9(analysis)-402.7(was)-402.6(conducted)-399.4(for)-400.7(the)-396.3(individual)-404.4(sub-)]TJ
-1.0137 -1.1174 TD
[(groups.)-424.5(As)-429.1(shown)-426.6(in)-422.8(Figure)-428.2(1,)-425(the)-430.8(BER)-427(prognostic)-426.9(index)]TJ
0 -1.1116 TD
[(score)-399.3(stratied)-398.1(patients)-403(into)-396.3(four)-396(distinct)-402(sub-groups.)-399.9(Sub-)]TJ
T*
[(group)-316.5(1)-317.9(had)-321.2(the)-315.6(best)-322.3(survival,)-318.7(whereas)-322.9(sub-group)-314.9(4)-317.9(had)-321.2(the)]TJ
0 -1.1174 TD
[(worst)-444(survival)-442(\()]TJ
/F6 1 Tf
6.831 0 TD
(p)Tj
/F7 1 Tf
.6681 0 TD
(<)Tj
/F4 1 Tf
.7142 0 TD
[(0.000001\))-6.5(.)-441.2(The)-443.4(survival)-442(of)-439.9(patients)-449.1(in)]TJ
-8.2133 -1.1116 TD
[(sub-group)-314.9(2)-312.1(\()]TJ
/F6 1 Tf
5.6733 0 TD
(p)Tj
/F7 1 Tf
.6681 0 TD
(<)Tj
/F4 1 Tf
.72 0 TD
[(0.001\))-314.2(and)-309.7(sub-group)-314.9(3)-312.1(\()]TJ
/F6 1 Tf
10.3329 0 TD
(p)Tj
/F7 1 Tf
.6681 0 TD
(<)Tj
/F4 1 Tf
.72 0 TD
[(0.000001\))-311.7(re-)]TJ
-18.7824 -1.1116 TD
[(mains)-186.4(poor)-194.4(compared)-192(with)-189.8(sub-group)-188.2(1.)-188.8(In)-186.5(patients)-189.9(who)-194.2(are)-189.9(at)]TJ
0 -1.1174 TD
[(high)-240.7(risk)-240.5(\(Nottingham)-240.4(index)-242.9(score)]TJ
/F7 1 Tf
14.1113 0 TD
(>)Tj
/F4 1 Tf
.72 0 TD
[(3.4\))-242.9(and)-240.6(did)-239.6(not)-239.6(receive)]TJ
-14.8312 -1.1116 TD
[(adjuvant)-339.7(endocrine)-341.8(therapy,)-336.1(the)-338.7(survival)-338.3(of)-342(patients)-339.6(in)-336.4(sub-)]TJ
T*
[(group)-276.2(4)-277.6(remains)-281.9(poor)-275.1(\(Fig.)-278.5(2A\).)-284(Together,)-280.8(the)-275.3(data)-283.3(provides)]TJ
0 -1.1174 TD
[(evidence)-411(that)-403.2(BER)-409.7(expression)-410.5(status)-410.8(may)-403.1(have)-409.9(prognostic)]TJ
0 -1.1116 TD
[(signicance)-235.5(in)-232.7(patients.)-233.6(We)-236(also)-230.1(evaluated)-239.5(whether)-229.9(BER)-237(had)]TJ
T*
[(predictive)-406.5(signicance)-414.1(in)-405.5(patients)-408.8(with)-408.7(ER)]TJ
/F7 1 Tf
7.3823 0 0 6.5614 487.3889 318.5574 Tm
(+)Tj
/F4 1 Tf
9.843 0 0 9.843 496.7432 314.192 Tm
[(tumours)-406.3(who)]TJ
-18.8861 -1.1116 TD
[(received)-197.9(adjuvant)-201.5(tamoxifen)-198(therapy.)-197.9(As)-198.7(shown)-202(in)-192.4(Figure)-197.8(2B,)]TJ
0 -1.1174 TD
[(patients)-236(in)-238.5(sub-group)-234.3(4)-237.2(had)-234.9(the)-235(worst)-236.7(survival)-240.4(and)-234.8(patients)-241.7(in)]TJ
0 -1.1116 TD
[(sub-groups)-442.5(2)-438.8(and)-442.2(3)-438.8(had)-442.2(intermediate)-445.8(prognosis)-441.6(compared)]TJ
T*
[(with)-362.6(sub-group)-361(1.)-361.6(These)-365.9(data)-364(suggest)-365.7(that)-362.9(BER)-363.7(expression)]TJ
0 -1.1174 TD
[(may)-282.2(predict)-281(benets)-280.5(from)-282(endocrine)-284.2(therapy.)]TJ
/F10 1 Tf
8.9663 0 0 8.9663 310.8472 237.4866 Tm
[(Deregulated)-333.5(BER)-333.8(is)-337.9(associated)]TJ
0 -1.2266 TD
[(with)-330.2(aggressive)-335.9(ER)]TJ
/F7 1 Tf
6.7246 0 0 5.9768 389.3668 230.5133 Tm
(+)Tj
/F10 1 Tf
8.9663 0 0 8.9663 397.1905 226.4881 Tm
[(breast)-334.6(cancers)]TJ
/F4 1 Tf
9.843 0 0 9.843 320.8251 210.0472 Tm
[(The)-408.8(data)-415.8(presented)-416.5(earlier)-414.6(suggest)-411.8(that)-414.8(BER)-415.5(expression)]TJ
-1.0137 -1.1116 TD
[(status)-284.1(may)-282.2(be)-279.8(a)-284.5(promising)-281.9(biomarker.)-281.9(To)-285.6(provide)-279.7(additional)]TJ
ET
59.754 174.217 490.167 .22676 re
f
59.754 86.627 490.167 .28342 re
f
59.754 155.225 490.167 .28348 re
f
BT
/F9 1 Tf
9.845 0 0 9.845 67.6913 179.8866 Tm
(Table)Tj
/F4 1 Tf
3.0002 0 TD
(1.)Tj
/F9 1 Tf
1.2496 0 TD
[(Multivariate)-330.4(Cox)-337.6(Proportional)-336(Hazards)-329.4(Model)-333.7(in)-337.3(Estrogen)-332.2(Receptor-Positive)-335.2(Breast)-334.8(Cancers)]TJ
/F6 1 Tf
-5.056 -1.86 TD
[(Variables)-11729.9(Beta)]TJ
/F4 1 Tf
20.6559 0 TD
(p)Tj
/F6 1 Tf
.501 0 TD
[(-Value)-1799.4(Risk)-334.5(ratio)-1260.5(Risk)-334.5(ratio)-333.4(95%)-332.2(lower)-1262.5(Risk)-334.5(ratio)-333.4(95%)-332.2(upper)]TJ
/F4 1 Tf
-21.1569 -1.9061 TD
(XRCC1)Tj
/F7 1 Tf
14.3964 0 TD
(-)Tj
/F4 1 Tf
.7198 0 TD
(0.203954)Tj
/F8 1 Tf
5.0042 0 TD
(0.000219)Tj
/F4 1 Tf
5.6376 0 TD
[(0.815500)-3908.8(0.731907)-6327.4(0.908640)]TJ
-25.758 -1.0135 TD
[(FEN1)-12732.2(0.199727)]TJ
/F8 1 Tf
20.1204 0 TD
(0.004731)Tj
/F4 1 Tf
5.6376 0 TD
[(1.221069)-3908.8(1.063067)-6327.4(1.402556)]TJ
-25.758 -1.0135 TD
(SMUG1)Tj
/F7 1 Tf
14.3964 0 TD
(-)Tj
/F4 1 Tf
.7198 0 TD
(0.210251)Tj
/F8 1 Tf
5.0042 0 TD
(0.003919)Tj
/F4 1 Tf
5.6376 0 TD
[(0.810381)-3908.8(0.702510)-6327.4(0.934816)]TJ
-25.758 -1.0135 TD
(APE1)Tj
/F7 1 Tf
14.3964 0 TD
(-)Tj
/F4 1 Tf
.7198 0 TD
(0.245472)Tj
/F8 1 Tf
5.0042 0 TD
(0.000754)Tj
/F4 1 Tf
5.6376 0 TD
[(0.782335)-3908.8(0.678241)-6327.4(0.902406)]TJ
-25.758 -1.0077 TD
[(Lymph)-335.5(node)-333.4(stage)-335.5(\(continuous\))-2149.6(0.705445)]TJ
/F8 1 Tf
20.1204 0 TD
(0.0000001)Tj
/F4 1 Tf
5.6376 0 TD
[(2.024747)-3908.8(1.662938)-6327.4(2.465276)]TJ
-25.758 -1.0135 TD
[(Histological)-338.2(grade)-7648.9(0.616616)]TJ
/F8 1 Tf
20.1204 0 TD
(0.0000001)Tj
/F4 1 Tf
5.6376 0 TD
[(1.852647)-3908.8(1.510526)-6327.4(2.272256)]TJ
8.7511 0 0 8.7511 67.748 74.8346 Tm
[(Bold)-333.4(values)-335.8(indicate)-333.8(signicant)]TJ
/F6 1 Tf
13.1964 0 TD
(p)Tj
/F4 1 Tf
.5053 0 TD
(-values.)Tj
-13.7017 -1.0236 TD
[(APE1,)-404.4(AP)-407.9(endonuclease)-403.6(1;)-404.5(FEN1,)-404.4(ap)-405.6(endonuclease)-410.1(1;)-404.5(SMUG1,)-406.6(single-strand)-404.9(monofunctional)-406(uracil)-406(glycosylase-1;)-406.3(XRCC1,)-401.6(X-ray)]TJ
-.9134 -1.0236 TD
[(cross-complementation)-334.7(group)-336.1(1)-329.2(protein.)]TJ
ET
59.754 731.735 239.301 .51025 re
f
59.754 553.096 239.301 .51019 re
f
59.754 553.096 .51024 179.15 re
f
298.545 553.096 .51022 179.15 re
f
BT
/F3 1 Tf
8.9663 0 0 8.9663 65.7637 718.0156 Tm
(Innovation)Tj
/F4 1 Tf
9.843 0 0 9.843 75.7417 701.5746 Tm
[(The)-334(role)-334(of)-336.2(estrogen)-339.3(receptor)-334.9(\(ER\)-dependent)-343.7(cellular)]TJ
-1.0137 -1.1116 TD
[(proliferation)-253.2(signaling)-247.4(is)-249.8(well)-248.6(established)-257.5(in)-244.2(breast)-256.5(cancer)]TJ
T*
[(pathogenesis;)-495.9(however,)-498.1(very)-495.1(little)-498(is)-491.7(known)-496(about)-496.4(the)]TJ
T*
[(clinical)-479.4(relevance)-476.6(of)-474.5(ER-independent)-482.2(mechanisms.)-480.9(Es-)]TJ
0 -1.1174 TD
[(trogen)-370.7(and)-378.8(estrogen)-373.9(metabolites)-380(induce)-371.9(reactive)-376.5(oxygen)]TJ
0 -1.1116 TD
[(species)-293.2(generation)-291.2(that)-293.8(can)-293.6(promote)-292.4(oxidative)-289.1(DNA)-293.9(base)]TJ
T*
[(damage)-282(which)-278.4(is)-278.6(repaired)-283.1(by)-278.7(base)-283(excision)-281.9(repair)-279.7(\(BER\).)]TJ
0 -1.1174 TD
[(Impaired)-438.7(BER,)-436.2(therefore,)-437.3(could)-438.8(accelerate)-439.8(mutagenesis)]TJ
0 -1.1116 TD
[(and)-580.4(promote)-580.4(a)-578.2(mutator)-586.3(phenotype)-582.6(in)-578.3(estrogen-driven)]TJ
T*
[(breast)-331.4(cancers.)-332.4(The)-328.2(authors)-325.6(provide)-331.5(the)-327.1(rst)-326.7(comprehen-)]TJ
0 -1.1174 TD
[(sive)-224.4(clinical)-225.9(evidence)-226.7(that)-224.7(altered)-224.5(BER)-225.4(expression)-226.2(may)-224.6(be)]TJ
0 -1.1116 TD
[(associated)-666.4(with)-667.9(aggressive)-665.1(estrogen-ER-driven)-670.6(breast)]TJ
T*
[(cancers.)-297.8(Stratication)-300.3(by)-295.9(BER)-294.5(status)-295.6(may)-293.7(enable)-298.2(person-)]TJ
0 -1.1174 TD
[(alization)-284.6(of)-278.6(therapy)-280.8(in)-284.6(estrogen-driven)-284.9(breast)-285.3(cancers.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(BER)-338.6(IN)-335.1(ER-POSITIVE)-332.7(BREAST)-338.7(CANCER)]TJ
52.4612 0 TD
(2263)Tj
ET
endstream
endobj
53 0 obj
<>stream
hބTPTrcրsb%*"P (
,#8k@".`I1橭(Q"%[&M0qɿ}%t3g~w7AR=zEU)Eq1.TToo'`w75X`1lT(=$-[O=|7fTАgIWhϕ\i҃Y2Sb]i-6d
M:!Og"|c EtyF`E}Δc0O
J'aJeJ7!Q݄T!OR.xz Ujm[uz[}V=nw- "٤&E4b)]